<?xml version="1.0" encoding="UTF-8"?>
<p>In general terms, and specifically with this issue, we need to have a clear pathway for regulation based on solid scientific data. There is no “
 <italic>one-size-fits all approach</italic>” when looking at the relevance of pre-clinical data and the availability of clinical data for marketing approval. This applies to the comparability between innovators (original/ first approved medicinal products) and a similar formulation submitted for marketing approval or, when approved, looking at its clinical comparability: is it subject, or not, to interchangeability? (
 <xref rid="B16" ref-type="bibr">16</xref>).
</p>
